Johnson Fistel said it is investigating potential federal securities-law claims on behalf of investors in Corcept Therapeutics Incorporated, focusing on the company’s executive officers and whether shareholder losses can be recovered. The probe follows Corcept’s disclosure of an FDA Complete Response Letter for relacorilant and a later corrected version indicating the agency had previously raised concerns about the clinical development program, after which the stock fell sharply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602231221PRIMZONEFULLFEED9659330) on February 23, 2026, and is solely responsible for the information contained therein.